These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 12230483)

  • 1. Metabolic and laboratory effects of icodextrin.
    Gokal R; Moberly J; Lindholm B; Mujais S
    Kidney Int Suppl; 2002 Oct; (81):S62-71. PubMed ID: 12230483
    [No Abstract]   [Full Text] [Related]  

  • 2. Biocompatibility of icodextrin.
    Cooker LA; Holmes CJ; Hoff CM
    Kidney Int Suppl; 2002 Oct; (81):S34-45. PubMed ID: 12230480
    [No Abstract]   [Full Text] [Related]  

  • 3. Icodextrin: an alternative peritoneal dialysis fluid.
    Chhabra D; Nash K
    Expert Opin Drug Metab Toxicol; 2008 Nov; 4(11):1455-64. PubMed ID: 18950286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of clinical trial experience with icodextrin.
    Wolfson M; Ogrinc F; Mujais S
    Kidney Int Suppl; 2002 Oct; (81):S46-52. PubMed ID: 12230481
    [No Abstract]   [Full Text] [Related]  

  • 5. Allergic reactions to icodextrin in patients with renal failure.
    Divino Fiho JC
    Lancet; 2000 Apr; 355(9212):1364-5. PubMed ID: 10776767
    [No Abstract]   [Full Text] [Related]  

  • 6. Icodextrine and insulin resistance in continuous ambulatory peritoneal dialysis patients.
    Canbakan M; Sahin GM
    Ren Fail; 2007; 29(3):289-93. PubMed ID: 17497442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis.
    Babazono T; Nakamoto H; Kasai K; Kuriyama S; Sugimoto T; Nakayama M; Hamada C; Furuya R; Hasegawa H; Kasahara M; Moriishi M; Tomo T; Miyazaki M; Sato M; Yorioka N; Kawaguchi Y;
    Am J Nephrol; 2007; 27(4):409-15. PubMed ID: 17622748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Icodextrin - still a cause for concern with blood glucose monitoring in continuous ambulatory peritoneal dialysis patients with diabetes.
    Slim S; Griffiths MJ; Gama R
    Ann Clin Biochem; 2007 Mar; 44(Pt 2):196-7. PubMed ID: 17362588
    [No Abstract]   [Full Text] [Related]  

  • 9. [Icodextrin in peritoneal dialysis therapy].
    Grzegorzewska AE; Antczak-Jedrzejczak D
    Przegl Lek; 1999; 56(12):812-6. PubMed ID: 10789195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Dialysis.
    Gokal R; Mistry CD; Peers EM
    Perit Dial Int; 1995; 15(6):226-30. PubMed ID: 7578498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical experience with icodextrin. Multicenter study].
    Guerrero A; Montes R; Martín-Herrera C; Ruiz A; Remón C; Fernández-Ruiz EJ; Pérez-Bañasco V; Benítez M; Martínez-Benavides E; Martínez-González JM; Torán D; Tejuca F; Páez C; del Pino MD
    Nefrologia; 2001; 21(6):574-80. PubMed ID: 11881427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of fill volume on ultrafiltration with icodextrin in children on chronic peritoneal dialysis.
    Rousso S; Banh TM; Ackerman S; Piva E; Licht C; Harvey EA
    Pediatr Nephrol; 2016 Oct; 31(10):1673-9. PubMed ID: 27178072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Icodextrin: a review of its use in peritoneal dialysis.
    Frampton JE; Plosker GL
    Drugs; 2003; 63(19):2079-105. PubMed ID: 12962523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dialysis with icodextrin interferes with measurement of serum alpha-amylase activity.
    Schoenicke G; Grabensee B; Plum J
    Nephrol Dial Transplant; 2002 Nov; 17(11):1988-92. PubMed ID: 12401858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future of icodextrin as an osmotic agent in peritoneal dialysis.
    Pecoits-Filho R; Mujais S; Lindholm B
    Kidney Int Suppl; 2002 Oct; (81):S80-7. PubMed ID: 12230485
    [No Abstract]   [Full Text] [Related]  

  • 16. Potential hazards of polyglucose.
    Diaz-Buxo JA; Passlick-Deetjen J; Gotloib L
    ASAIO J; 2001; 47(6):602-7. PubMed ID: 11730195
    [No Abstract]   [Full Text] [Related]  

  • 17. Avoidable iatrogenic hypoglycemia in patients on peritoneal dialysis: the risks of nonspecific glucose monitoring devices and drug-device interaction.
    Firanek CA; Jacob DT; Sloand JA
    J Patient Saf; 2014 Dec; 10(4):218-21. PubMed ID: 23860196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Icodextrin as first treatment: reasons to be optimistic].
    Rivera M
    Nefrologia; 2009; 29(2):99-102. PubMed ID: 19396313
    [No Abstract]   [Full Text] [Related]  

  • 19. Hypoglycemic coma in a diabetic patient on peritoneal dialysis due to interference of icodextrin metabolites with capillary blood glucose measurements.
    Disse E; Thivolet C
    Diabetes Care; 2004 Sep; 27(9):2279. PubMed ID: 15333503
    [No Abstract]   [Full Text] [Related]  

  • 20. A novel "bimodal" use of icodextrin peritoneal dialysis solutions.
    Burkart J
    Kidney Int; 1998 Apr; 53(4):1089-90. PubMed ID: 9551423
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.